Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 71

1.

Pilot study of subcutaneous recombinant human interleukin 12 in metastatic melanoma.

Bajetta E, Del Vecchio M, Mortarini R, Nadeau R, Rakhit A, Rimassa L, Fowst C, Borri A, Anichini A, Parmiani G.

Clin Cancer Res. 1998 Jan;4(1):75-85.

2.

Phase I trial of subcutaneous recombinant human interleukin-12 in patients with advanced renal cell carcinoma.

Motzer RJ, Rakhit A, Schwartz LH, Olencki T, Malone TM, Sandstrom K, Nadeau R, Parmar H, Bukowski R.

Clin Cancer Res. 1998 May;4(5):1183-91.

4.

A phase I/II study of recombinant human interleukin-12 in patients with chronic hepatitis C.

Zeuzem S, Hopf U, Carreno V, Diago M, Shiffman M, Grüne S, Dudley FJ, Rakhit A, Rittweger K, Yap SH, Koff RS, Thomas HC.

Hepatology. 1999 Apr;29(4):1280-7.

PMID:
10094976
5.

Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies.

Atkins MB, Robertson MJ, Gordon M, Lotze MT, DeCoste M, DuBois JS, Ritz J, Sandler AB, Edington HD, Garzone PD, Mier JW, Canning CM, Battiato L, Tahara H, Sherman ML.

Clin Cancer Res. 1997 Mar;3(3):409-17.

6.
7.

A phase I/II study of recombinant human interleukin-12 in patients with chronic hepatitis B.

Carreño V, Zeuzem S, Hopf U, Marcellin P, Cooksley WG, Fevery J, Diago M, Reddy R, Peters M, Rittweger K, Rakhit A, Pardo M.

J Hepatol. 2000 Feb;32(2):317-24.

PMID:
10707873
8.

A phase I and pharmacokinetic study of subcutaneously-administered recombinant human interleukin-4 (rhuIL-4) in patients with advanced cancer.

Davis ID, Maher DW, Cebon JS, Green MD, Fox RM, McKendrick JJ, Rybak ME, Boyd AW.

Growth Factors. 2000;17(4):287-300.

PMID:
10801077
9.

Peripheral burst of tumor-specific cytotoxic T lymphocytes and infiltration of metastatic lesions by memory CD8+ T cells in melanoma patients receiving interleukin 12.

Mortarini R, Borri A, Tragni G, Bersani I, Vegetti C, Bajetta E, Pilotti S, Cerundolo V, Anichini A.

Cancer Res. 2000 Jul 1;60(13):3559-68.

10.

Phase I study of the intratumoral administration of recombinant canarypox viruses expressing B7.1 and interleukin 12 in patients with metastatic melanoma.

Triozzi PL, Allen KO, Carlisle RR, Craig M, LoBuglio AF, Conry RM.

Clin Cancer Res. 2005 Jun 1;11(11):4168-75.

11.

Phase I study of subcutaneously administered recombinant human interleukin 12 in patients with advanced renal cell cancer.

Portielje JE, Kruit WH, Schuler M, Beck J, Lamers CH, Stoter G, Huber C, de Boer-Dennert M, Rakhit A, Bolhuis RL, Aulitzky WE.

Clin Cancer Res. 1999 Dec;5(12):3983-9.

12.

Randomized multicenter phase II trial of subcutaneous recombinant human interleukin-12 versus interferon-alpha 2a for patients with advanced renal cell carcinoma.

Motzer RJ, Rakhit A, Thompson JA, Nemunaitis J, Murphy BA, Ellerhorst J, Schwartz LH, Berg WJ, Bukowski RM.

J Interferon Cytokine Res. 2001 Apr;21(4):257-63.

PMID:
11359657
13.

Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma.

de Gast GC, Klümpen HJ, Vyth-Dreese FA, Kersten MJ, Verra NC, Sein J, Batchelor D, Nooijen WJ, Schornagel JH.

Clin Cancer Res. 2000 Apr;6(4):1267-72.

14.
15.

Phase I study of intraperitoneal recombinant human interleukin 12 in patients with Müllerian carcinoma, gastrointestinal primary malignancies, and mesothelioma.

Lenzi R, Rosenblum M, Verschraegen C, Kudelka AP, Kavanagh JJ, Hicks ME, Lang EA, Nash MA, Levy LB, Garcia ME, Platsoucas CD, Abbruzzese JL, Freedman RS.

Clin Cancer Res. 2002 Dec;8(12):3686-95.

16.

Phase I trial of subcutaneous recombinant human interleukin-2 in patients with metastatic melanoma.

Eton O, Rosenblum MG, Legha SS, Zhang W, Jo East M, Bedikian A, Papadopoulos N, Buzaid A, Benjamin RS.

Cancer. 2002 Jul 1;95(1):127-34.

17.
18.

Combination interleukin-2 and doxorubicin in advanced adult solid tumors: circumvention of doxorubicin resistance in soft-tissue sarcoma?

Le Cesne A, Vassal G, Farace F, Spielmann M, Le Chevalier T, Angevin E, Valteau-Couanet D, Fizazi K, Cojean I, Llombard A, Tursz T, Escudier B.

J Immunother. 1999 May;22(3):268-77.

PMID:
10335487
19.

Phase I study of recombinant interleukin-21 in patients with metastatic melanoma and renal cell carcinoma.

Thompson JA, Curti BD, Redman BG, Bhatia S, Weber JS, Agarwala SS, Sievers EL, Hughes SD, DeVries TA, Hausman DF.

J Clin Oncol. 2008 Apr 20;26(12):2034-9. doi: 10.1200/JCO.2007.14.5193. Epub 2008 Mar 17.

PMID:
18347008
20.

Intratumoral administration of recombinant human interleukin 12 in head and neck squamous cell carcinoma patients elicits a T-helper 1 profile in the locoregional lymph nodes.

van Herpen CM, Looman M, Zonneveld M, Scharenborg N, de Wilde PC, van de Locht L, Merkx MA, Adema GJ, de Mulder PH.

Clin Cancer Res. 2004 Apr 15;10(8):2626-35.

Supplemental Content

Support Center